Kornimate/medical-research-clean huggingface dataset:
effectiveness of zinc supplementation in management of patients with symptomatic benign migratory glossitis

Conditions: Benign Migratory Glossitis

Summary: effectiveness of zinc supplementation in management of patients with symptomatic benign migratory glossitis. zinc supplements seems to be a therapeutic option as migratory glossitis is a chronic disease knowing that it needs no treatment. zinc deficiency can probably be a causative factor in filiform papillae atrophy. studies have mentioned the role of zinc in wound healing and maintaining a healthy epithelium, as well as regeneration of filiform papillae. geographic tongue is a disorder that affects the lingual papillae. it has been shown that zinc sulfate can contribute to the treatment of geographic tongue positively.

forty-eight patients diagnosed with symptomatic benign migratory glossitis will be selected from oral medicine, periodontology and oral diagnosis department, faculty of dentistry, ain shams university. research ethical committee will review the protocol and the procedure will be explained to the patients and they will sign an informed consent. seven days after the diagnosis and selection of patients with (bmg), the atrophic areas will be determined and the patients will attend a control checkup in order to exclude those with constant changing patterns of the red atrophic areas with raised keratotic margins. only those patients who presented with constant atrophic areas with keratotic margins at the control checkup will be included during the study evaluation process, then the selected patient according the following inclusion and exclusion criteria will be randomly allocated into two groups. patients met the eligibility criteria will be randomly assigned for 2 different groups using computer generated allocation concealment. group i: will include 24 patients with symptomatic bmg receiving zinc supplementation once daily and zinc rich diet for one month. (study group).group ii: will include 24 patients with symptomatic bmg receiving zinc rich diet only for one month. (control group). intensity of the discomfort will be monitored by the patients using the visual analogue scale (vas). saliva will be collected from all included patients to evaluate zinc levels before treatment and one month after treatment only.

Eligibility criteria:
inclusion criteria: 1. both genders are eligible. 2. adults above 18 years old. 3. patients who presented at the control checkup with constant atrophic areas with raised keratotic margins. 4. patients who diagnosed with symptomatic geographic tongue. exclusion criteria: 1. patients with anemia, oral candidiasis, and indicators for localized irritations (dental caries, affected teeth, sharp teeth edges, dental calculus, faulty dental fillings, and faulty prosthetic procedures). 2. psoriatic patients. 3. vulnerable patients (prisoners, persons with mental disabilities or physical handicaps, children, neonates and pregnant women)

Keywords: benign migratory glossitis zinc geographic tongue
evaluation of non-surgical and arthroscopic treatment for hip microinstability

Conditions: Musculoskeletal Abnormalities; Hip Injuries

Summary: microinstability of the hip joint is an important cause of hip pain and reduced hip function in young and active individuals. hip microinstability is due to extraphysiologic hip motion and could be secondary to acetabular dysplasia, connective tissue disorder, macrotrauma, microtrauma, iatrogenic- and idiopathic causes. treatment for hip microinstability is initiated with non-surgical treatment consisting of physiotherapy aimed mainly at stability. if non-surgical treatment fails, surgery with arthroscopic plication of the hip joint capsule is the preferred method. this study evaluates non-surgical and arthroscopic treatment for hip microinstability regarding hip function and adverse events.

this is a prospective cohort study evaluating 26 participants above 18 years of age undergoing non-surgical and surgical treatment for microinstability of the hip joint. participants with findings on physical examination and imaging suggestive of hip microinstability will undergo six months of physiotherapy aimed at stabilizing the hip joint. if non-surgical treatment fails, a diagnostic hip arthroscopy will be performed, and if hip microinstability is confirmed, the participants will undergo a plication of the hip joint capsule. participants will be evaluated with patient-reported outcome scores (proms) and strength- and function tests at time of enrollment and at 6-, 12- and 24 months following treatment. the primary outcome is hip function determined by proms and strength- and function tests. secondary outcomes include health-related quality of life (hrql), sport activity level and adverse events.

Eligibility criteria:
inclusion criteria: * hip microinstability * minimum 18 years old exclusion criteria: * hip osteoarthritis * severe hip dysplasia * perthes disease or avascular necrosis of the femoral head * previous surgery to the hip joint

Keywords: arthroscopy physiotherapy
prognosis of patients with infective endocarditis and risk stratification value of biomarkers (endeavor）

Conditions: Infective Endocarditis

Summary: in this study, by establishing a clinical cohort of infective endocarditis, we observed the natural prognosis and influencing factors in the process of disease development and regression; we used multi-omics technology to understand the prognostic value of its biomarkers, and provided new ideas and evidence for the pathogenesis, clinical diagnosis and treatment of ie.

infective endocarditis is an inflammation of the inner lining of the heart valves or ventricular walls caused by direct infection of the heart by bacteria, fungi and other microorganisms via the bloodstream route. at present, the clinical diagnosis of ie is mainly based on a combination of typical symptoms, imaging and blood culture, etc. finding more sensitive means and more accurate indicators for early detection of ie flora distribution characteristics is of great significance for the prevention and targeted treatment of ie. therefore, in this study, by establishing a clinical cohort of infective endocarditis, we observed the natural prognosis and influencing factors in the process of disease development and regression; we used multi-omics technology to understand the prognostic value of its biomarkers, and provided new ideas and evidence for the pathogenesis, clinical diagnosis and treatment of ie.

Eligibility criteria:
inclusion criteria: * patients with clinically confirmed infective endocarditis exclusion criteria: * patients refuse to sign informed consent form * patients who combined with serious systemic diseases, cannot tolerate the acquisition of biological samples

Keywords: infective endocarditis prognosis major adverse cardiac and cerebrovascular event
vinorelbine in unresectable or metastatic esophageal and gastric adenocarcinoma

Conditions: Esophageal Cancer; Gastric Cancer; Stomach Cancer

Summary: the purpose of this study is to collect anti-tumor activity of vinorelbine when given to patients with esophageal or gastric tumors. we will also collect information on the toxicities of vinorelbine in these patients.

* patients will receive vinorelbine intravenously once per week for eight weeks. these treatments will be repeated after the initial eight weeks as long as the patient continues to receive benefit from the treatment. if the patient experiences significant toxicities, the dose may be reduced or the chemotherapy may be discontinued. * before beginning treatment and during therapy, routine laboratory tests, scans and x-rays will be done to check the body's response to treatment. a physical exam will be done at the start of the study and before each course of treatment. scans will be done after eight weeks of therapy. * patients will remain on this study as long as their disease does not become worse or they do not experience severe side effects.

Eligibility criteria:
inclusion criteria: * locally unresectable or metastatic esophageal adenocarcinoma. locally unresectable or metastatic gastric adenocarcinoma. only patients with measurable tumors are eligible. * no more than one prior chemotherapy regimen * ecog performance status of 0-1 * life expectancy of \> 12 weeks * greater than or equal to 1,200 calorie/day intake * anc \> 1,500/mm3 * ast \< 3 x uln * total bilirubin \< 2.0 ng/dl * platelets \> 100,000/mm3 * serum creatinine \< 2.0 mg/dl exclusion criteria: * prior therapy with vinca alkaloids * chemotherapy within the past three weeks * clinically apparent central nervous system metastases or carcinomatous meningitis * peripheral neuropathy \> 1

Keywords: gastric adenocarcinoma esophageal adenocarcinoma vinorelbine
investigation of low back pain level on symptoms in chronic consipation

Conditions: Low Back Pain; Constipation

Summary: consipation is the most common digestive complaint in the general population

chronic constipation and low back pain are two common and often co-existing health conditions that affect millions of people worldwide. on the surface, these conditions appear to be unrelated and are associated with different anatomical sites (gastrointestinal tract and musculoskeletal system). however, a growing body of research is beginning to shed light on the complex interplay between chronic constipation and low back pain, highlighting potential links between these seemingly disparate health conditions. common etiologic factors such as neuromuscular function, chronic inflammation and lifestyle-related variables are known to exist

Eligibility criteria:
inclusion criteria: * 18-65 ages * rome iii diagnostic criteria exclusion criteria: * severe heart or kidney diseaseprevious gastrointestinal, spinal or pelvic surgery other than cholecystectomy, hysterectomy or appendectomy neurological diseases such as * multiple sclerosis, stroke, parkinson's disease or spinal injury, * impaired awareness (mini-mental score \< 15), * legal blindness, pregnancy, * rectal prolapse * anal fissure and altered constipation and diarrhea pattern.

Keywords: pain low back pain constipation
evaluation of liver fibrosis following surgical-induced weight loss

Conditions: Obesity

Summary: obesity is a frequent disease with an increased prevalence, estimated to 12.4% in france (obepi study 2006). non alcoholic fatty liver disease (nafld) and non alcoholic steatohepatitis (nash) both complicate morbid obesity and could be responsible for the development of liver fibrosis and consequently of liver cirrhosis. bariatric surgery has been widely used in obese patients to reduce their weight but also to decrease morbidity conditions related to obesity. it could be involved in an improvement in liver lesions observed in obese patients. to evaluate the severity of liver lesions, the gold standard is pathological examination of the liver using percutaneous or surgical biopsies, with a scoring called fibrosis score stage. alternative less invasive techniques have been developed to evaluate liver lesions. these tests are commonly used in clinical hepatology and consisted of serum levels determination of fibrosis markers (fibrotest, transthyretin). the aim of this study is to evaluate the evolution of fibrosis scores during weight loss in a population of patients operated on for morbid obesity ( bmi \> 40kg/m2 or bmi\> 35kg/m2 with comorbidity). the primary end point is to evaluate the concordance between fibrotest and transthyretin serum levels. the number of patients has been calculated on the basis of a concordance ( kendall test) superior to 70% in patients with grade f1 fibrosis that represents about 40% of morbid obese patients. a total of 255 patients has to be enrolled in this study. according to the number of patients operated on in the 3 centres (\>150/year), the time for recruitment is 12 months. secondary end points will evaluate in these patients the excess weight loss, the improvement in fibrosis liver tests and the correlation with improvement in other obesity- related conditions, according to surgical procedures.


Eligibility criteria:
inclusion criteria: * patients operated on for morbid obesity (bmi \>40kg/m2 or \>35kg/m2 associated with comorbidity) exclusion criteria: * contraindications to morbid obesity surgery

Keywords: morbid obesity bariatric surgery nash liver fibrosis fibrotest
comparison of mobilization and met post-traumatic elbow stiffness

Conditions: Elbow Fracture

Summary: the purpose of this study is to find the effects of mobilization and muscle energy technique in patients with post-traumatic elbow stiffness.

a randomized control trial was conducted at benazir bhutto hospital, rawalpindi. the sample size with reference to parent article was 10 calculated through open epi tool. but 30 patients were included in the study to increase the statistical power of analysis. the participants were divided into two interventional groups i.e. group a and group b, each having 15 participants. the study duration was 1 year. sampling technique applied was non probability purposive sampling technique. random allocation will be through sealed envelope method into two treatment group i.e. group a and group b. only 18-35 years old patients (both male and female) with post-traumatic elbow stiffness were included in the study. tools that were used in the study are nprs, dash questionnaire, tampa scale and goniometer. total duration of treatment for both groups was 3 weeks, 3 days a week. pre and post assessment was done. data was analyzed through spss version 23.

Eligibility criteria:
inclusion criteria: * patients with post-operative elbow stiffness after distal end extra-articular humerus fractures. * patients with proximal radius ulna fractures. * minimum immobilization period of 3 weeks exclusion criteria: * any ligament injury * patients with diabetes * patients with ra * patients with pathological fractures * revision surgeries * neuro-vascular disorders.

Keywords: post traumatic elbow stiffness pain elbow disability fracture
trial to evaluate the efficacy and safety of substrate ablation of monomorphic ventricular tachycardia

Conditions: Monomorphic Ventricular Tachycardia

Summary: to compare the efficacy and safety of substrate-based radiofrequency catheter ablation vs. antiarrhythmic drug therapy in patients with ischemic cardiomyopathy and scar-related sustained monomorphic ventricular tachycardia.

sustained monomorphic ventricular tachycardia remains an important source of morbidity and mortality in patients surviving a myocardial infarction. icd´s have been proven to reduce mortality in this patients population, nonetheless, recurrent arrhythmia and icd shocks are known to negatively impact ventricular function and are associated with worsening heart failure and mortality. we devised a controlled, randomized, parallel, single blind, phase iv clinical trial with the aim of comparing the efficacy and safety of substrate-based radiofrequency catheter ablation vs. antiarrhythmic drug therapy in patients with ischemic cardiomyopathy and scar-related sustained monomorphic ventricular tachycardia, implanted with an icd.

Eligibility criteria:
inclusion criteria: * ischemic cardiomyopathy, with ischemic myocardial scar * sustained monomorphic ventricular tachycardia * age \> 18 years * prior icd implantation exclusion criteria: * vt storm * nyha functional class iv * additional indication for antiarrhythmic drug therapy * contraindication for both study drugs (amiodarone and sotalol). * uncontrolled myocardial ischemia. * lv thrombus. * non-ischemic vt substrate. * contraindications for anticoagulation. * prior substrate ablation in the previous 6 months * cr \> 2.5 mg/dl * mitral and aortic mechanical valvular prosthesis

Keywords: ventricular tachycardia ischemic cardiomyopathy catheter ablation antiarrhythmic drug therapy icd
alberta physical activity and breast cancer prevention (alpha) trial

Conditions: Breast Neoplasms

Summary: the purpose of the alpha trial is to examine the physiologic changes that occur in a woman's body when she begins exercising that may be related to a change in her risk of getting breast cancer.

the goal of this study is to examine how a one-year exercise intervention, as compared to a usual sedentary lifestyle, influences specific biologic mechanisms that are hypothesized to be operative in the association between physical activity and breast cancer risk. these biologic mechanisms include sex hormone concentrations (estrone, estradiol and sex-hormone binding globulin); measures of adiposity and obesity; mammographic density; insulin-like growth factors; and insulin resistance. a two-centered, two-armed randomized controlled trial (rct) of exercise and risk factors for breast cancer will be conducted. approximately 334 postmenopausal, sedentary women will be recruited to the study. participants will be randomized to one of two groups: an exercise intervention, or a control group. the intervention group will undertake five weekly exercise sessions of 60 minutes each; three will be facility-based and two will be home-based each week. the edmonton and calgary exercise oncology facilities will be working in collaboration, and each will include both the controls and exercise intervention arms of the trial. the exercise intervention will last for 12 months. the control group will be asked not to change their usual level of activity during that time. baseline assessments will be obtained of serum sex hormones (estrone and estradiol), measures of obesity and adiposity, mammographic density, serum insulin growth factor (igf)-1, insulin resistance, aerobic capacity, and psychosocial health measures. at the end of the study, all baseline assessments will be repeated and compared between the two groups. this study will specifically address identified gaps in knowledge, in terms of examining the simultaneous effect of physical activity on several biologic mechanisms in a controlled trial setting, building on evidence from the only other randomized controlled trial on this topic. strengths of the proposal include the multi-centered setting (utilizing facilities in both calgary and edmonton), and the collaboration of an experienced multi-disciplinary research team from across north america.

Eligibility criteria:
inclusion criteria: * female * age 50-74 at baseline * postmenopausal * moderately sedentary lifestyle * live in calgary or edmonton, alberta, canada * english-speaking * willing to be randomized * body-mass index 22.0-40.0 * breast tissue density \>=0% exclusion criteria: * previous invasive cancer in last 5 years * major co-morbidities * unable to participate in exercise program * current smoker * current excessive drinker * hormone replacement therapy use in previous 2 years * drugs that may influence one or more study outcomes

Keywords: breast neoplasms exercise physical activity estrone estradiol adiposity breast density mammographic density insulin-like growth factor i insulin resistance women postmenopause
impact of a telemonitoring device on the occurever at home in children at risk of chemotherapy-induced neutropenia

Conditions: Oncopediatrics; Febrile Neutropenia

Summary: the goal of this clinical trial is to evaluate the feasibility of the study, measured by the acceptability rate of patients to be recruited in a study proposing temperature monitoring at home, by a remote monitoring device or by the visit of an ide at home (in association with the usual educational sessions), to children at risk of febrile neutropenia, from families with psycho-social vulnerabilities. the main questions it aims to answer are: * will participants adhere to the telemonitoring system? * is the intervention feasible, in terms of the device's failure to record temperature data? * will parents behave appropriately when using the device? * how satisfied will parents and caregivers be? * what will be the physical tolerance of the device? * on an exploratory basis, will the remote monitoring system be effective for months? researchers will compare : * patients using the telemonitoring device for continuous temperature monitoring at home, in combination with education sessions on temperature monitoring and the device * with patient with temperature monitoring at home by a nurse, 2 times a day, in combination with education sessions on temperature monitoring (without the telemonitoring device at home)


Eligibility criteria:
inclusion criteria: patient * aged 0 to 17 inclusive * followed in the pediatric onco-hematology department * primo-diagnosed with solid or hematological cancer (incident case) * having received a first cycle of chemotherapy * whose family has psycho-social vulnerabilities assessed by the froger et al. tool, indicating a need for an ide to support the family in monitoring the patient. exclusion criteria: patient: * with a dermatosis contraindicating the use of the device * refusing to participate in the study
recurrent stenoses in arteriovenous fistula (avf) for dialysis access: cutting balloon angioplasty combined with paclitaxel drug coated balloon angioplasty, an observational clinical study

Conditions: Dialysis Access Malfunction

Summary: to determine if cutting balloon angioplasty combined with deb angioplasty provides a higher primary patency after treatment of recurrent stenoses compared with cutting balloon angioplasty or angioplasty using deb alone in the venous outflow avfs. for cutting balloon angioplasty in venous stenosis, the primary patency after 12 months is 55-60% (9,16) and in recurrent stenoses up to 48%(10). we hypothesise that deb angioplasty after cutting balloon angioplasty leads to improved primary patency at 12 months.


Eligibility criteria:
inclusion criteria: * recurrent stenoses (within 1 year after angioplasty) in the venous outflow of avfs for dialysis access (\> 0.5cm from av anastomosis up to cephalic arch) * successful guidewire crossing of target lesion * ≥ 21 years old * informed and valid consent given. * patient willing and able to return for follow up . exclusion criteria: 1. thrombosed avfs or occlusions in the access circuit 2. significant cephalic arch (central perpendicular portion of the cephalic vein) or central vein stenoses. 3. \> 3 stenosed segments (lesions are considered separate if they are separated by at least 2 cm normal vessel.) 4. only potential target lesion located in cephalic arch, central veins or anastomotic lesions. 5. only de novo stenoses identifiable as target lesion. 6. target lesion resistant to cutting balloon angioplasty (\>30% residual stenosis with incomplete effacement of the lesion during cutting balloon angioplasty) 7. target lesion not treatable with the available sizes of cutting balloon (4-7mm) and drug eluting balloon (up to 8mm) so native reference vessel \ 8mm. 8. lesion in excess of 8 cm 9. unable to take dual antiplatelet therapy for 1 month and/or aspirin for 6 months 10. coagulopathy (pt or ptt \>1.5 times the median of normal range) or thrombocytopenia (platelet count \<50,000 /μl) that cannot be managed adequately with periprocedural transfusion. 11. patient on warfarin. 12. known allergy to iodinated contrast that cannot be managed adequately with pre-procedure medication. 13. allergy / contraindication to dual anti-platelet therapy (aspirin and clopidogrel or ticlopidine) or paclitaxel. 14. acute infection over proposed puncture site. 15. women who are breastfeeding, pregnant or planning on becoming pregnant during study. 16. participant with medical conditions, which in the opinion of the investigator may cause non-compliance with protocol. 17. currently participating in an investigational drug, biologic or device trial that may have an impact on the dialysis access or previous enrolment in this study.

Keywords: paclitaxel coated balloon cutting balloon recurrent stenosis